Danielle Antalffy
Stock Analyst at UBS
(3.36)
# 1,041
Out of 4,667 analysts
169
Total ratings
51.81%
Success rate
1.3%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYK Stryker | Maintains: Neutral | $366 → $370 | $387.08 | -4.41% | 6 | Oct 30, 2024 | |
| ATRC AtriCure | Maintains: Buy | $35 → $40 | $36.03 | +11.02% | 12 | Oct 30, 2024 | |
| ABT Abbott Laboratories | Maintains: Buy | $143 → $146 | $115.93 | +25.94% | 11 | Oct 17, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $90 → $75 | $69.80 | +7.46% | 12 | Sep 10, 2024 | |
| MDT Medtronic | Upgrades: Neutral | $76 → $90 | $84.20 | +6.89% | 7 | Aug 15, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $112 → $107 | $109.27 | -2.08% | 4 | Aug 8, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Neutral | $6.5 → $7 | $7.98 | -12.28% | 5 | Aug 7, 2024 | |
| DXCM DexCom | Maintains: Buy | $163 → $95 | $75.24 | +26.26% | 8 | Jul 26, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $74 → $90 | $90.49 | -0.54% | 11 | Apr 25, 2024 | |
| INMD InMode | Maintains: Neutral | $24 → $26 | $18.24 | +42.54% | 3 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $44.82 | +67.34% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $153.52 | +17.25% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $184.17 | +74.84% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $3.32 | -32.23% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $32.33 | +33.00% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $541.82 | -48.69% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $30.15 | +49.25% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $44.81 | -68.76% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $266.58 | +5.03% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $55 | $0.73 | +7,478.89% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $12.90 | +8.53% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $86.45 | +15.67% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $9.19 | +30.58% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $92.70 | -67.64% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $57.26 | -21.41% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $85 | $4.23 | +1,909.46% | 10 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $95 | $49.00 | +93.88% | 6 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $221.29 | +24.27% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $3.97 | +403.78% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $9.46 | +343.97% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.31 | +867.74% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.91 | +1,539.70% | 1 | Sep 1, 2020 |
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $387.08
Upside: -4.41%
AtriCure
Oct 30, 2024
Maintains: Buy
Price Target: $35 → $40
Current: $36.03
Upside: +11.02%
Abbott Laboratories
Oct 17, 2024
Maintains: Buy
Price Target: $143 → $146
Current: $115.93
Upside: +25.94%
Edwards Lifesciences
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $69.80
Upside: +7.46%
Medtronic
Aug 15, 2024
Upgrades: Neutral
Price Target: $76 → $90
Current: $84.20
Upside: +6.89%
Zimmer Biomet Holdings
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $109.27
Upside: -2.08%
Treace Medical Concepts
Aug 7, 2024
Maintains: Neutral
Price Target: $6.5 → $7
Current: $7.98
Upside: -12.28%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $75.24
Upside: +26.26%
Boston Scientific
Apr 25, 2024
Maintains: Buy
Price Target: $74 → $90
Current: $90.49
Upside: -0.54%
InMode
Feb 14, 2024
Maintains: Neutral
Price Target: $24 → $26
Current: $18.24
Upside: +42.54%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $44.82
Upside: +67.34%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $153.52
Upside: +17.25%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $184.17
Upside: +74.84%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $3.32
Upside: -32.23%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $32.33
Upside: +33.00%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $541.82
Upside: -48.69%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $30.15
Upside: +49.25%
May 6, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $44.81
Upside: -68.76%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $266.58
Upside: +5.03%
May 5, 2022
Maintains: Outperform
Price Target: $65 → $55
Current: $0.73
Upside: +7,478.89%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $12.90
Upside: +8.53%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $86.45
Upside: +15.67%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $9.19
Upside: +30.58%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $92.70
Upside: -67.64%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $57.26
Upside: -21.41%
Feb 24, 2022
Maintains: Outperform
Price Target: $105 → $85
Current: $4.23
Upside: +1,909.46%
Feb 24, 2022
Maintains: Outperform
Price Target: $85 → $95
Current: $49.00
Upside: +93.88%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $221.29
Upside: +24.27%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $3.97
Upside: +403.78%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $9.46
Upside: +343.97%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.31
Upside: +867.74%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.91
Upside: +1,539.70%